ProfileGDS5678 / 1437408_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 63% 61% 61% 59% 61% 65% 63% 64% 61% 60% 61% 61% 62% 61% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.7890563
GSM967853U87-EV human glioblastoma xenograft - Control 23.6206661
GSM967854U87-EV human glioblastoma xenograft - Control 33.6499261
GSM967855U87-EV human glioblastoma xenograft - Control 43.4768559
GSM967856U87-EV human glioblastoma xenograft - Control 53.6078861
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.9373165
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.8578963
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.8615964
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.6313861
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.57160
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.6684361
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.6206261
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.7194362
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.6505261